EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...

Antares' (ATRS) Vibex QuickShot auto injector restored and maintained testosterone levels in a Phase II study of 29 patients. The testosterone-replacement market was worth $2.8B in sales in 2013.

* Antares Pharma Inc - submitted a new drug application (nda) to U.S. Food And Drug Administration (FDA) for quickshot testosterone Sign up here. * Antares Pharma Inc - quickshot testosterone auto ...

The auto injector market represents a rapidly expanding segment within the global pharmaceutical delivery systems industry, driven by the increasing prevalence of chronic diseases and the growing ...

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...

Phillips-Medisize, in collaboration with its customer, Ascendis Pharma, was recently recognized with a third industry award for the Skytrofa Auto-Injector. The Red Dot Award recognizes the drug ...